מתוטרקסאט אבווה 100 מגמל

Ülke: İsrail

Dil: İbranice

Kaynak: Ministry of Health

Aktif bileşen:

METHOTREXATE

Mevcut itibaren:

NOVARTIS ISRAEL LTD

ATC kodu:

L01BA01

Farmasötik formu:

תרכיז להכנת תמיסה לאינפוזיה

Kompozisyon:

METHOTREXATE 100 MG/ML

Uygulama yolu:

תוך-שרירי, תוך-עורקי, תוך-ורידי, תוך חדרי, תוך-שדרתי

Reçete türü:

מרשם נדרש

Tarafından üretildi:

EBEWE PHARMA GES.M.B.H NFG.KG, AUSTRIA

Terapötik grubu:

METHOTREXATE

Terapötik alanı:

METHOTREXATE

Terapötik endikasyonlar:

Antineoplastic chemotherapy: treatment of gestational choriocarcinoma, chorioadenoma destruents and hydatidiform mole. Palliation of acute lymphocytic leukemia. In the treatment and prophylaxis of meningeal leukemia. Greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukemias in children. In combination with other anticancer agents, Methotrexate may be used for the induction of remission, but is most commonly used in maintenance of induced remissions. Abitrexate may be used alone or in combination with other antineoplastics in the management of breast cancer, epidermoid cancers of the head and neck, lung cancer (particularly squamous cell and small cell types), bladder cancer and osteogenic cancer. Methotrexate is effective in the treatment of the advanced stages (III and IV Peter's Staging System) of lymphosarcoma, particularly in children, and in advanced cases of mycosis fungoides. Psoriasis: because of the high risk attending its use, Methotrexate is indicated only in the

Yetkilendirme tarihi:

2023-09-30